Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02514655

Simple Mechanical Device to Control Pressure in the Balloon of the Endotracheal Tube to Prevent Ventilator-acquired Pneumonia

Hypothesis: Nosten® device is able to reduce the time of underinflated balloon and removes excess pressure. This device may thus reduce the risk of ventilator-acquired pneumonia (VAP) and early tracheal lesions resulting from intubation with decreased discomfort, morbidity, and nursing workload.

The main objective of the investigators is to show that Nosten® device is more effective than monitoring and manual inflation of the balloon of the tracheal tube to prevent VAP occurrence.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service de Réanimation Médical et Toxicologique

Paris, 75010, France

Location status: Recruiting

Location contact

Bruno MEGARBANE, MD, PhD

CONTACT

[email protected]

(+33)1 49 95 64 91

About this study

Multicenter, controlled, prospective randomized open study with blinded assessment of the primary endpoint. Two groups are set up: one experimental group with the control of the cuff pressure by the Nosten® device versus one control group with the manual monitoring of the cuff pressure and inflation of the balloon.

Inclusion: All orotracheally intubated patients for an expected period > 48 hours will be selected. Inclusion will be decided using an algorithm adapted to each center to limit the number of inclusion per month without any biases.

The total number of required insclusion is 500, or 250 / group. This calculation is based on the assumption that a frequency of 25% of patients having at least one VAP in the reference strategy, ensuring a 80% power in the detection by Chi-2 test with a difference 10%. A bilateral risk of first species determined at 5% was considered.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged ≥18 years
  • Patients admitted in the ICU, mechanically ventilated and whose trachea was intubated by the oral route using tubes with catheter polyvinyl chloride "high-volume low pressure" and of standard shape tubes Intubation indication is decided by the physicians in charge according to the usual criteria of respiratory, neurological and /or hemodynamic failure
  • With an expected duration of mechanical ventilation > 48 hours

Exclusion criteria

  • Patients intubated by nasotracheal route
  • Patients with tracheotomy before admission
  • Patients intubated with a polyurethane balloon catheter or a polyvinyl chloride balloon catheter of conical shape
  • Previously intubated patients for > 48 hours before their possible recruitment
  • Moribund patients (terminal illness or care-limiting decision)
  • Minors protected or incapacitated patients
  • Patients with recently diagnosed ENT cancer
  • Patients with facial, thoracic, spinal or upper airway trauma
  • Patients burned, intoxicated by fire fumes or caustic ingestion
  • Patient pregnant or breastfeeding (or with known positive urine pregnancy test before inclusion)
  • Patient intubated with a subglottic suction tube
  • Unaffiliated patients to a social security
  • Patients included in any other scientific study that may interfere with the outcome criteria of this study. This includes any other study on tracheal intubation or mechanical ventilation, if the use of the pressure control device may interfere with its endpoint.

Treatment and study plan

Nosten® pressure control (it's not an antibiotic, but simple device)

Device

One experimental group with the control of the cuff pressure by Nosten® device

Manual pressure control

Other

One control group with the manual monitoring of the cuff pressure and inflation of the balloon

Primary outcomes

  1. Reduction of the incidence of VAP as defined according to the criteria of the American Thoracic Society (3 months after inclusion)

    Time frame: up to 3 months

    To prove that the Nosten® device is more effective than monitoring and manual inflation of the catheter balloon in reducing the occurrence of VAP.

Secondary outcomes

  1. Reduction in the tracheobronchial bacterial colonization assessed using the bacteriological examination of the tracheal aspiration (as long as the patient is intubated during 3 months after inclusion)

    Time frame: up to 3 months

    using the bacteriological examination of the tracheal aspiration during the intensive care hospitalization

  2. Reduction of clinically suspected Ventilator-Acquired Pneumonia (VAP)

    Time frame: up to 3 months

    before obtaining microbiological results needed to affirm the Ventilator-Acquired Pneumonia (VAP) according to the criteria of the American Thoracic Society (3 months)

  3. Reduction in the duration of antibiotic therapy administered to patients, if diagnosed with ventilator-aquired-pneumonia (VAP) (3 months)

    Time frame: up to 3 months

    Reduction of clinically suspected Ventilator-Acquired Pneumonia (VAP)

  4. Reduction in the periods of hyper-pressure and under-inflation (as long as the patient is intubated during 3 months after inclusion)

    Time frame: up to 3 months

    Using Nosten® device

  5. Reduction in the significant early laryngeal and tracheal injuries related to intubation (3 months)

    Time frame: up to 3 months

    using the tracheal ischemia score [Touat L. Intensive Care Med 2014]

Study contacts

Contact information is provided by the study sponsor or research team.

Bruno MEGARBANE, MD, PhD

CONTACT

[email protected]

(+33)1 49 95 64 91

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Role of a Simple Mechanical Device of Pressure Control in the Balloon of the Endotracheal Tube to Prevent Ventilator-acquired Pneumonia

Acronym: PAV-PROTECT

Important dates

Study start
2015
Primary completion
2015
Study completion
2026
First posted
Aug 4, 2015
Registry last updated
Jun 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.